HC Wainwright Has Weak Outlook for CorMedix FY2026 Earnings

CorMedix Inc (NASDAQ:CRMD – Free Report) – Analysts at HC Wainwright decreased their FY2026 earnings estimates for CorMedix in a research note issued to investors on Friday, November 13th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.38 per share for the year, down from their previous estimate of $0.54. The consensus estimate for CorMedix’s current full-year earnings is $0.52 per share. HC Wainwright also issued estimates for CorMedix’s Q4 2026 earnings at ($0.13) EPS, FY2029 earnings at $0.73 EPS and FY2030 earnings at $0.97 EPS.

Several other research firms have also weighed in on CRMD. UBS Group set a $19.00 target price on CorMedix in a report on Tuesday, November 10th. Wall Street Zen downgraded CorMedix from a “hold” rating to a “sell” rating in a report on Saturday. Royal Bank Of Canada increased their price target on CorMedix from $14.00 to $15.00 and gave the stock an “outperform” rating in a report on Tuesday, November 10th. Needham & Company LLC raised their price target on CorMedix from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, November 10th. Finally, Citigroup reiterated a “market outperform” rating on shares of CorMedix in a report on Tuesday, November 10th. Eight research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $15.22.

Read Our Latest Stock Report on CRMD

CorMedix Price Performance

CRMD opened at $4.82 on Tuesday. The company has a quick ratio of 2.36, a current ratio of 2.56 and a debt-to-equity ratio of 0.31. CorMedix has a 12 month low of $4.65 and a 12 month high of $13.02. The company has a fifty day simple moving average of $7.11 and a 200 day simple moving average of $7.55. The stock has a market cap of $375.67 million, a P/E ratio of 6.99, a P/E/G ratio of 0.90 and a beta of 1.48.

CorMedix (NASDAQ:CRMD – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). CorMedix had a return on equity of 27.12% and a net margin of 15.49%. The firm had revenue of $54.52 million for the quarter, compared to the consensus estimate of $51.76 million.

Insider Buying and Selling at CorMedix

In other news, CEO Joseph Todisco acquired 80,000 shares of CorMedix stock in a transaction dated Friday, November 13th. The stock was bought at an average cost of $4.89 per share, with a total value of $391,200.00. Following the completion of the transaction, the chief executive officer directly owned 854,749 shares of the company’s stock, valued at approximately $4,179,722.61. This represents a 10.33% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CorMedix

Hedge funds and other institutional investors have recently bought and sold shares of the company. Advisors Asset Management Inc. bought a new stake in CorMedix in the 3rd quarter valued at approximately $26,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in CorMedix during the 3rd quarter worth approximately $31,000. Kestra Advisory Services LLC grew its stake in shares of CorMedix by 142.9% during the 1st quarter. Kestra Advisory Services LLC now owns 10,200 shares of the company’s stock worth $69,000 after acquiring an additional 6,000 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of CorMedix during the 2nd quarter worth approximately $85,000. Finally, Allworth Financial LP bought a new position in shares of CorMedix during the 2nd quarter worth approximately $88,000. Institutional investors and hedge funds own 34.18% of the company’s stock.

CorMedix Company Profile

(Get Free Report)

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.

Read More

Earnings History and Estimates for CorMedix (NASDAQ:CRMD)

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.